Meirow D, Schenker J G
Department of Obstetrics and Gynecology, Hadassah University Hospital, Ein-Kerem, Jerusalem, Israel.
Eur J Obstet Gynecol Reprod Biol. 1995 Jan;58(1):59-65. doi: 10.1016/0028-2243(94)01940-9.
To collect results of gamete intrafallopian transfer on a large scale in order to compare treatment indications, results, and factors which influence the success rates; to evaluate whether gamete intrafallopian transfer is well-established and what the real place of this procedure is among other assisted reproduction techniques.
Data relating to gamete intrafallopian transfer were collected from World Reports, national registries of different countries and meta-analysis of medical publications during the years 1986-1991.
Official registries reported 47,200 treatment cycles and 18,759 treatment cycles were analysed from ten medical publications.
The procedure accounts for 13.5% of all assisted reproduction techniques but its popularity varies significantly among countries. The same indications for gamete intrafallopian transfer are followed by all countries, but great differences exist with regard to the proportional share of each etiology. Also, the share has changed considerably over the years. TREATMENT OUTCOME: 10,667 clinical pregnancies were reported which represent 24% of treatment cycles and 29% of ovum pick-up. The live birth rate was 23.3%; abortion rate, 22%; and ectopic pregnancy rate, 5.5%. The stillbirth rate was 2.3% and the malformation rate was 2.8%, not confined to specific organs or systems. There were 19.5% twins, 4.6% triplets and 0.3% quadruplets or more. The number of transferred oocytes influenced pregnancy rates: 28% for transfer of four oocytes and only 10% following transfer of one oocyte. The cause of infertility might influence the results and the poorest results are obtained for male factor infertility. In most cases correlation of success rates reported by leading units through medical publications closely resembles the overall national registries results. Indications for this treatment were broadened over the years, but its role among other assisted reproduction technologies is not agreed upon, especially for male factor and unexplained infertility.
Gamete intrafallopian transfer carries an overall higher pregnancy rate than in vitro fertilization. Quality control by professional or public associations should be established and more research employed over indications for treatment and results in order to establish when GIFT is the treatment of choice and when other modes of treatment should be preferred.
大规模收集输卵管内配子移植的结果,以比较治疗指征、结果及影响成功率的因素;评估输卵管内配子移植是否已确立,以及该程序在其他辅助生殖技术中的实际地位。
1986年至1991年期间,从《世界报告》、不同国家的国家登记处以及医学出版物的荟萃分析中收集与输卵管内配子移植相关的数据。
官方登记处报告了47200个治疗周期,从十篇医学出版物中分析了18759个治疗周期。
该程序占所有辅助生殖技术的13.5%,但其受欢迎程度在不同国家有显著差异。各国对输卵管内配子移植的指征相同,但每种病因的比例份额存在很大差异。此外,这些份额多年来也有很大变化。治疗结果:报告了10667例临床妊娠,占治疗周期的24%,占取卵的29%。活产率为23.3%;流产率为22%;异位妊娠率为5.5%。死产率为2.3%,畸形率为2.8%,不限于特定器官或系统。双胞胎占19.5%,三胞胎占4.6%,四胞胎及以上占0.3%。移植卵母细胞的数量影响妊娠率:移植四个卵母细胞时妊娠率为28%,移植一个卵母细胞时仅为10%。不孕原因可能影响结果,男性因素不孕的结果最差。在大多数情况下,领先单位通过医学出版物报告的成功率与国家总体登记结果密切相似。多年来该治疗的指征有所扩大,但其在其他辅助生殖技术中的作用尚无定论,尤其是对于男性因素和不明原因不孕。
输卵管内配子移植的总体妊娠率高于体外受精。专业或公共协会应建立质量控制,并对治疗指征和结果进行更多研究,以确定何时输卵管内配子移植是首选治疗方法,以及何时应优先选择其他治疗方式。